The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19
- PMID: 34548877
- PMCID: PMC8445778
- DOI: 10.1016/j.fbr.2021.09.003
The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19
Abstract
The Coronavirus outbreak globally has changed the medical system and also led to a shortage of medical facilities in both developing and underdeveloped countries. The COVID19 disease, being novel in nature along with high infectivity and frequent mutational rate, has been termed to be fatal across the globe. The advent of infection by SARS-CoV-2 has brought a myriad of secondary complications and comorbidities resulting in additional challenges to the health care system induced by novel therapeutic procedures. The emerging variant with respect to the Indian subcontinent and the associated genetic mutations have worsened the situation at hand. Proper clinical management along with epidemiological studies and clinical presentations in scientific studies and trials is necessary in order to combat the simultaneous waves of emerging strains. This article summarizes three of the major fungal outbreaks in India namely mucormycosis, candidiasis and aspergillosis, and elaborates their subtypes, pathogenesis, symptoms and treatment and detection techniques. A detail of future therapeutics under consideration are also elaborated along with a general hypothesis on how COVID19 is related to immunological advances leading to major widespread fungal infection in the country. The factors that contribute in promoting virus proliferation and invasive fungal infections include cell-mediated immunity, associated immunocompromised conditions and treatment protocols that slows down immune mechanisms. To better comprehend a fungal or bacterial outbreak, it is very important to conduct audits mediated through multicenter national and state research teams for recognizing patterns and studying current cases of fungal infection in both healthy and comorbid groups of COVID19 patients.
Keywords: Amphotericin-B; Aspergillosis; COVID19; Candidiasis; Fungus; Mucormycosis.
© 2021 British Mycological Society. Published by Elsevier Ltd. All rights reserved.
Figures





Similar articles
-
COVID19 associated mucormycosis: Is GRP78 a possible link?J Infect Public Health. 2021 Oct;14(10):1351-1357. doi: 10.1016/j.jiph.2021.09.004. Epub 2021 Sep 10. J Infect Public Health. 2021. PMID: 34538732 Free PMC article. Review.
-
Fungal pathogens and COVID-19.Curr Opin Microbiol. 2023 Oct;75:102365. doi: 10.1016/j.mib.2023.102365. Epub 2023 Aug 23. Curr Opin Microbiol. 2023. PMID: 37625261 Review.
-
COVID-19-associated mucormycosis - "The Black fungus" with associated invasive aspergillosis and actinomycosis infection: Series of 5 cases in the Indian scenario.Indian J Pathol Microbiol. 2023 Oct-Dec;66(4):823-828. doi: 10.4103/ijpm.ijpm_507_22. Indian J Pathol Microbiol. 2023. PMID: 38084540
-
COVID19 associated mucormycosis: A review.J Family Med Prim Care. 2022 Feb;11(2):418-423. doi: 10.4103/jfmpc.jfmpc_1186_21. Epub 2022 Feb 16. J Family Med Prim Care. 2022. PMID: 35360784 Free PMC article. Review.
-
Post-COVID-19 Fungal Infection in the Aged Population.Vaccines (Basel). 2023 Feb 27;11(3):555. doi: 10.3390/vaccines11030555. Vaccines (Basel). 2023. PMID: 36992139 Free PMC article. Review.
Cited by
-
Lower Concentrations of Amphotericin B Combined with Ent-Hardwickiic Acid Are Effective against Candida Strains.Antibiotics (Basel). 2023 Mar 3;12(3):509. doi: 10.3390/antibiotics12030509. Antibiotics (Basel). 2023. PMID: 36978378 Free PMC article.
-
Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients.J Fungi (Basel). 2022 Jan 6;8(1):58. doi: 10.3390/jof8010058. J Fungi (Basel). 2022. PMID: 35049999 Free PMC article. Review.
-
Nanotechnology-based fungal detection and treatment: current status and future perspective.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan;397(1):77-97. doi: 10.1007/s00210-023-02662-8. Epub 2023 Aug 19. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37597093 Review.
-
Diffuse Lung Disease in Convalescents of COVID-19.Her Russ Acad Sci. 2022;92(4):412-417. doi: 10.1134/S1019331622040037. Epub 2022 Sep 6. Her Russ Acad Sci. 2022. PMID: 36091843 Free PMC article.
-
Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19.Curr Microbiol. 2024 Oct 9;81(11):400. doi: 10.1007/s00284-024-03916-1. Curr Microbiol. 2024. PMID: 39384659 Review.
References
-
- Anaissie E.J., Stratton S.L., Dignani M.C., Summerbell R.C., Rex J.H., Monson T.P., Spencer T., Kasai M., Francesconi A., Walsh T.J. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin. Infect. Dis. : An Off Publ Infect Dis Soc Am. 2002;34(6):780–789. doi: 10.1086/338958. - DOI - PubMed
-
- Andrianaki A.M., Kyrmizi I., Thanopoulou K., Baldin C., Drakos E., Soliman S.S.M., Shetty A.C., Mccracken C., Akoumianaki T., Stylianou K., Ioannou P., Pontikoglou C., Papadaki H.A., Tzardi M., Belle V., Etienne E., Beauvais A., Samonis G., Kontoyiannis D.P., Andreakos E., Bruno V.M., Ibrahim A.S., Chamilos G. Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat. Commun. 2018;9(1) doi: 10.1038/S41467-018-05820-2. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous